Fig. 5.

Two-way sensitivity analysis with visualization of the incorporated scenarios. Caption: This cross table shows the levels of cost-effectiveness at different willingness to pay levels of TIL therapy compared to ipilimumab when the Progression Free Survival (PFS) rate after 1 year changes and the costs of TIL vary. The dotted line represents the base case analysis. The incorporated scenarios are represented by letters. a = “TIL more effective”, b = “Combination therapy”, c = “Less IL2 treatment”, d= “TIL production outsourced”, e = “Automatic TIL production”. The scenario “low-cost competition” was not possible to present in this graph because it affects the costs of ipilimumab instead of the costs of TIL therapy. The colors do not always correspond with the results in Figs. 3 and 4 because we evaluated the rounded numbers of costs and PFS rate